Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Raw Materials (2022 - 2026)

Envoy Medical's Raw Materials history spans 5 years, with the latest figure at $1.2 million for Q1 2026.

  • On a quarterly basis, Raw Materials fell 13.55% to $1.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.2 million, a 13.55% decrease, with the full-year FY2025 number at $1.3 million, down 8.95% from a year prior.
  • Raw Materials hit $1.2 million in Q1 2026 for Envoy Medical, down from $1.3 million in the prior quarter.
  • Over the last five years, Raw Materials for COCH hit a ceiling of $1.4 million in Q1 2025 and a floor of $1.0 million in Q4 2022.
  • Historically, Raw Materials has averaged $1.3 million across 5 years, with a median of $1.3 million in 2024.
  • Biggest five-year swings in Raw Materials: rose 19.28% in 2024 and later fell 13.55% in 2026.
  • Tracing COCH's Raw Materials over 5 years: stood at $1.0 million in 2022, then increased by 15.05% to $1.2 million in 2023, then increased by 19.28% to $1.4 million in 2024, then decreased by 8.95% to $1.3 million in 2025, then fell by 1.43% to $1.2 million in 2026.
  • Business Quant data shows Raw Materials for COCH at $1.2 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.